Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men
评估多西环素暴露后预防以减少 PrEP 使用者和男男性行为 HIV 感染者的性传播感染
基本信息
- 批准号:10599168
- 负责人:
- 金额:$ 141.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-12 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdherenceAdverse eventAgeAntibiotic ResistanceAntibioticsAnusBacteriaCRISPR/Cas technologyCaucasiansChlamydiaCitiesClinicClinicalControl GroupsDataDiseaseDoxycyclineDrug resistanceEffectivenessEnrollmentEpidemicEvaluationEventFecesFranceFutureGoalsGonorrheaHIVHIV InfectionsHIV SeronegativityHourIncidenceIndividualInfectionInfection ControlIntentionInterventionMethodsMolecularNasopharynxNeisseriaNeisseria gonorrhoeaeNucleic AcidsOropharyngealParticipantPatient Self-ReportPatientsPersonsPharmaceutical PreparationsPharyngeal structurePoliciesPolicy MakerPopulationPopulation HeterogeneityPrevention strategyProphylactic treatmentPublic HealthRandomizedRecording of previous eventsRectumRiskSafetySan FranciscoSerologySex BehaviorSexually Transmitted DiseasesStaphylococcus aureusSwabSyphilisTechniquesTestingTetracycline ResistanceTimeToxic effectUnsafe SexUrinearmbacterial resistancecollegecolon microbiotacommensal microbeseffectiveness evaluationgut microbiomehigh riskhigh risk menhost microbiotainfection rateinnovationmen who have sex with menmetagenomic sequencingopen labeloropharyngeal swabpathogenpre-exposure prophylaxispreventprimary outcomerectalresistance genesecondary outcometransmission process
项目摘要
Abstract
Sexually transmitted infections (STI) rates are at an all-time high in the US, with striking increases of gonorrhea
(GC), chlamydia (CT), and syphilis among men who have sex with men (MSM). Pre-exposure prophylaxis (PrEP)
against HIV is increasingly being used by at-risk MSM populations in the US; remarkably, this population has
bacterial STI incidence rates as high as >50% per year. MSM living with HIV are also disproportionately impacted
by STIs, with high incidence and reinfection rates of syphilis, 50% higher rates of GC and 30% higher rates of
CT compared to MSM without HIV. These data highlight the pressing need for innovative and effective strategies
to reduce STIs in high-risk MSM, both those living with HIV and HIV-negative MSM taking PrEP. One potential
STI control strategy is post-exposure prophylaxis (PEP) with doxycycline. This strategy demonstrated efficacy
in a recent randomized open-label trial in 232 HIV-negative MSM on event-driven PrEP in France (IPERGAY
study). Doxycycline PEP resulted in a 47% relative reduction in new bacterial STIs (GC, CT, or syphilis), with
rare adverse events and no difference in self-reported sexual behavior between arms. However, IPERGAY
participants were older, mostly Caucasian and college educated, and highly adherent to event driven PrEP (as
opposed to daily PrEP, the US norm). Thus, the results of the IPERGAY doxycycline PEP study may not reflect
the advantages and risks of this strategy in diverse populations, including MSM living with HIV, whose adherence,
sexual practices, and sexual networks may differ from HIV-uninfected MSM. Furthermore, a previously
unexplored and important concern about doxycycline PEP is selection of antibiotic resistance among the target
bacterial STI pathogens, colonizing bacteria that can cause disease (e.g., Staph aureus), commensal Neisseria
spp which could transmit tetracycline (TCN) resistance genes to GC, and in the gut microbiome which may serve
as a reservoir of transmissible TCN resistance to colonic microbiota. Based on the IPERGAY data, doxycycline
PEP appears to be a promising innovative strategy to address the STI epidemic, particularly among higher risk
MSM with a history of STIs and condomless sex. A sufficiently-powered, high-quality study is needed to evaluate
the effectiveness in both MSM living with HIV and MSM on PrEP and the impact on drug resistance in the target
bacterial STIs and normal host microbiota. We propose a randomized open label trial to assess the effectiveness
of doxycycline PEP and impact on antibiotic resistance in 380 MSM living with HIV and 380 MSM on PrEP at
public health clinics in San Francisco and Seattle. Our Specific Aims are to: 1) Evaluate the effectiveness,
tolerability, acceptability, and adherence profile of doxycycline PEP to reduce STI incidence among MSM
taking PrEP or living with HIV. 2) Assess the effect of doxycycline PEP on selection of tetracycline
resistance in Neisseria gonorrhoeae, Staphylocccus aureus and commensal flora, including Neisseria
spp and the gut microbiome. This study will provide critical data about doxycycline PEP in 2 cities with high
PrEP coverage and high STI rates in order to inform policy.
摘要
在美国,性传播感染(STI)的发病率处于历史最高水平,淋病的发病率急剧上升
(GC)衣原体(CT)和梅毒在男男性行为者(MSM)中。暴露前预防(PrEP)
在美国,越来越多的高危MSM人群使用抗艾滋病毒药物;值得注意的是,
细菌性STI发病率高达每年50%以上。感染艾滋病毒的男男性行为者也受到不成比例的影响
梅毒的发病率和再感染率高,GC的发病率高出50%,
CT与无艾滋病毒的MSM相比。这些数据突出表明迫切需要创新和有效的战略
减少高危男男性接触者的性传播感染,包括艾滋病毒感染者和艾滋病毒阴性的男男性接触者服用PrEP。
性传播感染控制策略是使用强力霉素进行暴露后预防。这一策略证明了有效性
在法国最近一项随机开放标签试验中,232名HIV阴性MSM接受了事件驱动的PrEP(IPERGAY
研究)。强力霉素PEP导致新发细菌性STI(GC、CT或梅毒)相对减少47%,
罕见的不良事件,两组之间自我报告的性行为没有差异。然而,IPERGAY
参与者年龄较大,大部分是白人和大学教育,高度坚持事件驱动的PrEP(作为
与美国标准的每日PrEP相反)。因此,IPERGAY多西环素PEP研究的结果可能无法反映
该策略在不同人群中的优势和风险,包括感染艾滋病毒的男男性行为者,其依从性,
性行为和性网络可能与未感染艾滋病毒的MSM不同。此外,此前
关于多西环素PEP的未探索的和重要的关注是在靶点中选择抗生素抗性,
细菌性STI病原体,可引起疾病的定殖细菌(例如,金黄色葡萄球菌)、葡萄球菌
spp可以将四环素(TCN)抗性基因传递给GC,并且在肠道微生物组中可能起作用
作为对结肠微生物群的可传播TCN抗性的储存库。根据IPERGAY的数据,强力霉素
PEP似乎是一个有希望的创新战略,以解决性传播感染的流行,特别是在高风险
有性传播感染史和无安全套性行为史的男男性接触者。需要一项强有力的高质量研究来评估
艾滋病毒感染者和MSM对PrEP的有效性以及对目标人群耐药性的影响
细菌性传播感染和正常宿主微生物群。我们建议进行一项随机开放标签试验来评估
多西环素PEP对380名感染HIV的MSM和380名接受PrEP的MSM抗生素耐药性的影响
弗朗西斯科和西雅图的公共卫生诊所。我们的具体目标是:1)评估有效性,
多西环素PEP降低MSM STI发病率耐受性、可接受性和依从性
服用PrEP或感染艾滋病毒。2)评价强力霉素PEP对四环素筛选的影响
淋病奈瑟菌、金黄色葡萄球菌和口腔植物群(包括奈瑟菌)的耐药性
spp和肠道微生物组。本研究将提供关于强力霉素PEP在2个城市的关键数据,
PrEP覆盖率和高性传播感染率,以便为政策提供信息。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Doxycycline post-exposure prophylaxis for sexually transmitted infections in South Africa.
强力霉素暴露后预防南非性传播感染。
- DOI:10.4102/sajhivmed.v24i1.1510
- 发表时间:2023
- 期刊:
- 影响因子:1.7
- 作者:Peters RPH;McIntyre JA;Garrett N;Brink AJ;Celum CL;Bekker LG
- 通讯作者:Bekker LG
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CONNIE L CELUM其他文献
CONNIE L CELUM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CONNIE L CELUM', 18)}}的其他基金
Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men
评估多西环素暴露后预防以减少 PrEP 使用者和男男性行为 HIV 感染者的性传播感染
- 批准号:
10376318 - 财政年份:2019
- 资助金额:
$ 141.24万 - 项目类别:
Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men
评估多西环素暴露后预防以减少 PrEP 使用者和男男性行为 HIV 感染者的性传播感染
- 批准号:
9914211 - 财政年份:2019
- 资助金额:
$ 141.24万 - 项目类别:
PrEP for Young South African Women: Evaluating Uptake by Risk Screening or a Decision Support Tool and Scaled Adherence Support Using a SMART Design
南非年轻女性的 PrEP:通过风险筛查或决策支持工具以及使用 SMART 设计的大规模依从性支持来评估其接受情况
- 批准号:
9404078 - 财政年份:2017
- 资助金额:
$ 141.24万 - 项目类别:
HIV self-testing and PrEP to increase testing and prevention uptake among male partners and improve postpartum ART use in PMTCT B+ programs in Uganda
HIV 自我检测和 PrEP 可提高男性伴侣的检测和预防接受率,并改善乌干达 PMTCT B 项目中产后 ART 的使用
- 批准号:
9895861 - 财政年份:2017
- 资助金额:
$ 141.24万 - 项目类别:
PrEP for Young South African Women: Evaluating Uptake by Risk Screening or a Decision Support Tool and Scaled Adherence Support Using a SMART Design
南非年轻女性的 PrEP:通过风险筛查或决策支持工具以及使用 SMART 设计的大规模依从性支持来评估其接受情况
- 批准号:
10175041 - 财政年份:2017
- 资助金额:
$ 141.24万 - 项目类别:
Interventions to decrease HIV infectiousness in Uganda
降低乌干达艾滋病毒感染率的干预措施
- 批准号:
8722105 - 财政年份:2013
- 资助金额:
$ 141.24万 - 项目类别:
Interventions to decrease HIV infectiousness in Uganda
降低乌干达艾滋病毒感染率的干预措施
- 批准号:
8447165 - 财政年份:2012
- 资助金额:
$ 141.24万 - 项目类别:
Multi-component, Targeted HIV Prevention for sub-Saharan Africa: PreventionRx
撒哈拉以南非洲地区多组成部分、有针对性的艾滋病毒预防:PreventionRx
- 批准号:
8077722 - 财政年份:2010
- 资助金额:
$ 141.24万 - 项目类别:
Multi-component, Targeted HIV Prevention for sub-Saharan Africa: PreventionRx
撒哈拉以南非洲地区多组成部分、有针对性的艾滋病毒预防:PreventionRx
- 批准号:
8130323 - 财政年份:2010
- 资助金额:
$ 141.24万 - 项目类别:
Interventions to decrease HIV infectiousness in Uganda
降低乌干达艾滋病毒感染率的干预措施
- 批准号:
8044884 - 财政年份:2010
- 资助金额:
$ 141.24万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 141.24万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 141.24万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 141.24万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 141.24万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 141.24万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 141.24万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 141.24万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 141.24万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 141.24万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 141.24万 - 项目类别:
Fellowship Programs














{{item.name}}会员




